.jpg)
Metabolic Disorders
Male glucocorticoid-induced osteoporosis: teriparatide more effective than risedronate
J Bone Miner Res. 2013 Jun;28(6):1355-68. doi: 10.1002/jbmr.187092 men with glucocorticoid-induced osteoporosis (GIO) were randomized to receive either daily injections of 20 ug teriparatide or weekly oral tablets of 35 mg risedronate to determine the effects of these treatments on improvements in bone mineral density (BMD), as assessed with dual X‐ray absorptiometry (DXA) and high-resolution quantitative computed tomography (HRQCT). Results indicated that, although both treatments were generally similar at 6 months, improvements in bone mineral density significantly favoured the teriparatide group, compared to the risedronate group at 18 months. Similar trends were observed for vertebral strength and stiffness. Complications and adverse events were also similar for both groups.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.